| The safety and efficacy of brinzolamide 1%/timolol 0.5% fixed combination versus dorzolamide 2%/timolol 0.5% in patients with open-angle glaucoma or ocular hypertension. | |
| | |
MedLine Citation:
|
PMID: 19365194 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
PURPOSE: This study compared the intraocular pressure (IOP)-lowering efficacy of 2 fixed combination products, brinzolamide 1%/timolol 0.5% suspension (Azarga, Brinz/Tim) and dorzolamide 2%/timolol 0.5% solution (Dorz/Tim), in patients with open-angle glaucoma or ocular hypertension who required a change in therapy due to elevated IOP while receiving IOP-lowering medication. METHODS: This was a one-year, multicenter, randomized, double-masked, active-controlled, parallel-group trial of Brinz/Tim and Dorz/Tim. IOP assessments were taken at 8 and 10 AM at week 2 and months 3 and 9, and at 8 AM, 10 AM, and 4 PM at months 6 and 12. Primary efficacy was a noninferiority comparison of mean IOP at the three month 6 time points. RESULTS: Of the 437 patients enrolled, 220 dosed Brinz/Tim whereas 217 dosed Dorz/Tim twice daily. Brinz/Tim produced IOP-lowering efficacy comparable to Dorz/Tim, with the upper 95% confidence limits for the differences between groups within +1.5 mm Hg at all assessment times, including the month 6 primary efficacy time points, establishing noninferiority. Differences in means numerically favored Brinz/Tim at 9 of 12 study visits and times. The IOP reductions ranged from 7.2 to 9.2 mm Hg for Brinz/Tim and from 7.4 to 8.9 mm Hg for Dorz/Tim. Although a similar overall safety profile was observed between the 2 treatment groups, Brinz/Tim showed significantly less ocular irritation (2.7% vs. 10.6%; P=0.0009) than Dorz/Tim. CONCLUSIONS: Brinz/Tim suspension provides statistically significant and clinically relevant IOP-lowering efficacy that is noninferior to Dorz/Tim. Additionally, Brinz/Tim affords an ocular comfort advantage compared with Dorz/Tim. |
| | |
Authors:
|
Gianluca Manni; Phillipe Denis; Paul Chew; Elisabeth D Sharpe; Silvia Orengo-Nania; Michael A Coote; Guna Laganovska; Lasma Volksone; Thierry Zeyen; Isabella Filatori; John James; Tin Aung |
Related Documents
:
|
11322634 - Intraocular pressure-lowering efficacy of latanoprost in patients with normal-tension g... 15506604 - Intraocular pressure lowering efficacy of travoprost. 12701864 - Comparison of single-drop mitomycin c regime with other mitomycin c regimes in pterygiu... 12928274 - Latanoprost in port wine stain related paediatric glaucoma. 18670374 - Invasive treatment for renovascular disease. a twenty year experience from a population... 18482284 - Viral kinetic of hcv genotype-4 during pegylated interferon alpha 2a: ribavirin therapy. |
Publication Detail:
|
Type: Comparative Study; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Journal of glaucoma Volume: 18 ISSN: 1536-481X ISO Abbreviation: J. Glaucoma Publication Date: 2009 Apr-May |
Date Detail:
|
Created Date: 2009-04-14 Completed Date: 2009-07-01 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9300903 Medline TA: J Glaucoma Country: United States |
Other Details:
|
Languages: eng Pagination: 293-300 Citation Subset: IM |
Affiliation:
|
University of Rome, Tor Vergata, Bietti Foundation IRCSS, Rome, Italy. glmanni@inwind.it |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Administration, Topical Adrenergic beta-Antagonists / adverse effects, therapeutic use* Adult Aged Aged, 80 and over Carbonic Anhydrase Inhibitors / adverse effects, therapeutic use* Double-Blind Method Drug Combinations Female Glaucoma, Open-Angle / drug therapy* Humans Intraocular Pressure / drug effects* Male Middle Aged Ocular Hypertension / drug therapy Prospective Studies Sulfonamides / adverse effects, therapeutic use* Thiazines / adverse effects, therapeutic use* Thiophenes / adverse effects, therapeutic use* Timolol / adverse effects, therapeutic use* Tonometry, Ocular Treatment Outcome Young Adult |
| Chemical | |
Reg. No./Substance:
|
0/Adrenergic beta-Antagonists; 0/Carbonic Anhydrase Inhibitors; 0/Drug Combinations; 0/Sulfonamides; 0/Thiazines; 0/Thiophenes; 130693-82-2/dorzolamide; 138890-62-7/brinzolamide; 26839-75-8/Timolol |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Personality traits, depression, and objectively measured adherence to once-daily prostaglandin analo...
Next Document: Risk factors for developing avascular filtering bleb after fornix-based trabeculectomy with mitomyci...